| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We investigated the epilepsy-inducing actions of paraoxon with elevated [K+]e and the effects of atropine, pralidoxime, and selective muscarinic acetylcholine receptor (mAChR) antagonists on the actions of paragon.
paraoxon-induced cholinesterase inhibition elicited epileptic activity in elevated [K+]e but not normal [K+]e. Treatment for hyperkalemia likely prevents the development of epilepsy in organophosphate intoxication. Paraoxon-induced epileptic activity was inhibited by atropine but not by pralidoxime. Relatively weak mAChR activation likely elicited epileptic activity in 7.5 mM [K+]e. Atropine, rather than pralidoxime, may be effective at inhibiting organophosphate-induced epileptic activity.
|
